Tryptophan-substituted temporin-1CEb (I1WL5W) potently reduces MDR Klebsiella pneumoniae lung infection and biofilm in mice
Background
Multidrug-resistant Klebsiella pneumoniae (MDRKP) represents a critical public health threat, accounting for a significant portion of ICU isolates and posing substantial treatment challenges due to resistance to conventional antibiotics. This necessitates the exploration of alternative therapeutic strategies. Antimicrobial peptides (AMPs) offer a promising avenue, particularly those with enhanced membrane-disrupting capabilities. Tryptophan (Trp) substitutions in AMPs are known to improve their interaction with bacterial cell membranes, potentially boosting their antimicrobial efficacy and overcoming resistance mechanisms.
Study Design
Researchers generated three Trp-modified peptides (I4W, L12W, and I1WL5W) from temporin-1CEb by substituting Ile or Leu residues with Trp. They assessed their antibacterial effects against K. pneumoniae in vitro, focusing on membrane disruption mechanisms using assays like bacterial surface charge neutralization, membrane permeability, and integrity. Biofilm inhibition and degradation were also evaluated. The most potent candidate, I1WL5W, was then tested in a murine lung infection model induced by MDRKP 1203. Efficacy was determined by measuring bacterial counts, IL-6 and TNF-α levels in blood and lung tissues, and histopathological assessment of lung structure.
Results
Among the Trp-modified peptides, I4W and I1WL5W demonstrated superior antimicrobial activity and lower cytotoxicity compared to L12W. Mechanistic studies confirmed that these AMPs exert bactericidal effects by neutralizing bacterial surface charge, inserting into cell membranes, increasing both inner and outer membrane permeability, and disrupting overall membrane integrity. Notably, I1WL5W exhibited the most potent membrane-disrupting activity. The peptides also significantly impacted bacterial biofilms, not only inhibiting exopolysaccharide production and biofilm formation but also degrading preformed biofilms. In the murine lung infection model, treatment with I1WL5W resulted in:
reduced bacterial counts and levels of
IL-6andTNF-αin both the blood and lung tissues of MDRKP 1203-infected mice, alongside improved lung tissue structure compared to control treatment.
Key Findings
- I4W and I1WL5W showed superior antimicrobial activity and lower cytotoxicity compared to L12W.
- AMPs neutralize bacterial surface charge, insert into membranes, and increase permeability.
- I1WL5W exhibited the most potent membrane-disrupting activity against K. pneumoniae.
- Peptides inhibited biofilm formation and degraded preformed biofilms.
- I1WL5W reduced bacterial counts and
IL-6/TNF-αlevels in a murine lung infection model.
Why It Matters
This study highlights I1WL5W as a promising candidate for combating MDR Klebsiella pneumoniae infections, offering a novel mechanism of action that targets bacterial membranes and biofilms, which are critical for resistance and persistence. For peptide users and biohackers interested in antimicrobial strategies, this research underscores the potential of rational peptide design, specifically Trp-substitution, to enhance efficacy. While currently in preclinical stages, these findings provide valuable insights for developing new antimicrobial agents, particularly for difficult-to-treat infections. The ability to disrupt biofilms is a significant advantage, as biofilms often shield bacteria from antibiotics. Further research is needed to translate these findings into a usable clinical protocol, including detailed pharmacokinetics and safety profiles in higher organisms.
temporin-1ceb
i1wl5w
klebsiella-pneumoniae
mdr
antimicrobial-peptide
lung-infection